Rallybio Corporation RLYB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | 484.21% | -29.10% | -29.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00% | 484.21% | -29.10% | -29.10% |
| Cost of Revenue | -87.52% | -77.80% | -32.13% | -49.72% | -53.08% |
| Gross Profit | 87.07% | 80.79% | 35.80% | 50.50% | 53.65% |
| SG&A Expenses | 16.69% | 29.23% | 0.61% | -27.42% | -4.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.95% | -32.78% | -20.51% | -42.28% | -40.76% |
| Operating Income | 43.79% | 33.50% | 22.82% | 42.61% | 40.96% |
| Income Before Tax | 563.66% | 12.30% | 47.01% | 239.68% | 40.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 550.02% | 12.30% | 47.01% | 239.68% | 40.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 550.02% | 12.30% | 47.01% | 239.68% | 40.24% |
| EBIT | 43.79% | 33.50% | 22.82% | 42.61% | 40.96% |
| EBITDA | 43.66% | 33.33% | 22.58% | 42.75% | 41.00% |
| EPS Basic | 542.59% | 13.70% | 47.95% | 238.24% | 41.19% |
| Normalized Basic EPS | 556.03% | 37.70% | 25.77% | 45.41% | 41.19% |
| EPS Diluted | 534.98% | 13.70% | 47.95% | 238.24% | 41.19% |
| Normalized Diluted EPS | 548.26% | 37.70% | 25.77% | 45.41% | 41.19% |
| Average Basic Shares Outstanding | 1.68% | 1.63% | 1.79% | 1.04% | 1.62% |
| Average Diluted Shares Outstanding | 3.44% | 1.63% | 1.79% | 1.04% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |